Beijing Pearl Biotechnology Limited Liability Company Report issue

Government Phase 1 Phase 2

Organization Overview

First Clinical Trial
2016
NCT02896231
First Marketed Drug
2021
fluvastatin (lescol)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

BEIJING | Beijing Pearl Biotechnology Limited Liability Company